129 related articles for article (PubMed ID: 30252680)
1. Interaction Between Direct Factor Xa Inhibitors and Digoxin.
Sokol J; Nehaj F; Ivankova J; Mokan M
Am J Ther; 2019; 26(5):e649-e652. PubMed ID: 30252680
[No Abstract] [Full Text] [Related]
2. Anti-Xa Activity in Elderly Xabans-Treated Patients With Atrial Fibrillation.
Samoš M; Bolek T; Škorňová I; Stančiaková L; Urban L; Staško J; Galajda P; Kubisz P; Mokáň M
Am J Ther; 2020; 27(5):e507-e509. PubMed ID: 31356346
[No Abstract] [Full Text] [Related]
3. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
4. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
[TBL] [Abstract][Full Text] [Related]
5. Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care.
Gulilat M; Tang A; Gryn SE; Leong-Sit P; Skanes AC; Alfonsi JE; Dresser GK; Henderson SL; Rose RV; Lizotte DJ; Teft WA; Schwarz UI; Tirona RG; Kim RB
Can J Cardiol; 2017 Aug; 33(8):1036-1043. PubMed ID: 28754389
[TBL] [Abstract][Full Text] [Related]
6. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
7. Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery.
Hakeam HA; Alkhani M; Alyahya Z; Alawaji Z; Ofori S
J Cardiovasc Pharmacol; 2021 Dec; 78(6):867-874. PubMed ID: 34882113
[TBL] [Abstract][Full Text] [Related]
8. Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation.
Lin SY; Kuo CH; Yeh SJ; Tsai LK; Liu YB; Huang CF; Tang SC; Jeng JS
Clin Pharmacol Ther; 2020 Jan; 107(1):278-286. PubMed ID: 31376150
[TBL] [Abstract][Full Text] [Related]
9. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Kadokura T; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):1-9. PubMed ID: 23754514
[TBL] [Abstract][Full Text] [Related]
10. Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.
Rohr BS; Krohmer E; Foerster KI; Burhenne J; Schulz M; Blank A; Mikus G; Haefeli WE
Clin Pharmacokinet; 2024 Apr; 63(4):469-481. PubMed ID: 38393578
[TBL] [Abstract][Full Text] [Related]
11. Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption.
Kou W; Sodhi JK; Wu X; Benet LZ
Pharm Res; 2021 May; 38(5):795-801. PubMed ID: 33847849
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology and laboratory testing of the oral Xa inhibitors.
Samama MM; Meddahi S; Samama CM
Clin Lab Med; 2014 Sep; 34(3):503-17. PubMed ID: 25168939
[TBL] [Abstract][Full Text] [Related]
13. Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood: A diagnostic test study.
Pailleret C; Jourdi G; Siguret V; Gouin-Thibault I; Gandrille S; Stepanian A; Curis E; Golmard JL; Gaussem P; Le Bonniec B; Samama CM
Eur J Anaesthesiol; 2019 Jun; 36(6):449-456. PubMed ID: 30308522
[TBL] [Abstract][Full Text] [Related]
14. Apixaban and rivaroxaban in patients with cerebral venous thrombosis.
Covut F; Kewan T; Perez O; Flores M; Haddad A; Daw H
Thromb Res; 2019 Jan; 173():77-78. PubMed ID: 30481600
[No Abstract] [Full Text] [Related]
15. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
Frost CE; Song Y; Shenker A; Wang J; Barrett YC; Schuster A; Harris SI; LaCreta F
Clin Pharmacokinet; 2015 Jun; 54(6):651-62. PubMed ID: 25573421
[TBL] [Abstract][Full Text] [Related]
16. Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients With Atrial Fibrillation: A Pilot Study.
Bánovčin P; Škorňová I; Samoš M; Schnierer M; Bolek T; Kovář F; Staško J; Kubisz P; Mokáň M
J Cardiovasc Pharmacol; 2017 Oct; 70(4):263-266. PubMed ID: 28708713
[TBL] [Abstract][Full Text] [Related]
17. Normal prothrombin times in the presence of therapeutic levels of apixaban--in-vivo experience from King's College Hospital.
Patel JP; Chitongo PB; Czuprynska J; Roberts LN; Patel RK; Arya R
Br J Haematol; 2015 Apr; 169(1):152-3. PubMed ID: 25312941
[No Abstract] [Full Text] [Related]
18. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
19. Advances in oral anticoagulation therapy - What's in the pipeline?
Rao PSS; Burkart T
Blood Rev; 2017 Jul; 31(4):205-211. PubMed ID: 28185693
[TBL] [Abstract][Full Text] [Related]
20. Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.
Kucey M; Bolt J; Albers L; Bell A; Iroh N; Toppings J
Can J Hosp Pharm; 2016; 69(5):409-414. PubMed ID: 27826159
[No Abstract] [Full Text] [Related]
[Next] [New Search]